Agilent Technologies, Inc. (A) CFO Didier Hirsch Sells 1,200 Shares
Agilent Technologies, Inc. (NYSE:A) CFO Didier Hirsch sold 1,200 shares of the firm’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total value of $79,200.00. Following the sale, the chief financial officer now directly owns 164,202 shares of the company’s stock, valued at $10,837,332. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Didier Hirsch also recently made the following trade(s):
- On Thursday, August 31st, Didier Hirsch sold 20,000 shares of Agilent Technologies stock. The shares were sold at an average price of $64.00, for a total value of $1,280,000.00.
- On Tuesday, August 22nd, Didier Hirsch sold 72,545 shares of Agilent Technologies stock. The shares were sold at an average price of $62.38, for a total value of $4,525,357.10.
Shares of Agilent Technologies, Inc. (A) traded up 0.344% during midday trading on Thursday, reaching $65.665. The company’s stock had a trading volume of 1,006,952 shares. Agilent Technologies, Inc. has a one year low of $42.92 and a one year high of $66.42. The firm has a market cap of $21.13 billion, a price-to-earnings ratio of 33.865 and a beta of 1.30. The stock’s 50 day moving average price is $61.91 and its 200 day moving average price is $57.80.
Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.07. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.49 EPS. Analysts predict that Agilent Technologies, Inc. will post $2.32 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/14/agilent-technologies-inc-a-cfo-didier-hirsch-sells-1200-shares.html.
A has been the subject of several research reports. Jefferies Group LLC increased their price target on Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, May 23rd. Bank of America Corporation reiterated an “equal weight” rating on shares of Agilent Technologies in a research report on Tuesday, August 15th. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Deutsche Bank AG lifted their price target on Agilent Technologies from $58.00 to $62.00 and gave the company a “buy” rating in a research report on Monday, May 22nd. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research report on Wednesday, August 16th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $63.91.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Balentine LLC increased its position in shares of Agilent Technologies by 2.9% during the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after acquiring an additional 50 shares during the period. Sun Life Financial INC increased its holdings in Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after buying an additional 2,353 shares during the last quarter. Acrospire Investment Management LLC increased its holdings in Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after buying an additional 1,200 shares during the last quarter. Parallel Advisors LLC increased its holdings in Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after buying an additional 131 shares during the last quarter. Finally, Trust Co. of Vermont increased its holdings in Agilent Technologies by 1.8% in the second quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock valued at $166,000 after buying an additional 50 shares during the last quarter.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.